OBJECTIVE

To study the effect of 5-hydroxymethyluracil with angiogenic properties on patient survival and incidence of adverse cardiovascular events in long-term period after myocardial revascularization.

MATERIAL AND METHODS

A randomized study included two groups of patients: main group (87 patients) — perioperative treatment with 5-hydroxymethyluracil (5 days before and 14 days after CABG) in addition to standard therapy; control group (81 patients) — standard therapy. Both groups were comparable in gender, age, clinical and functional characteristics, as well as features of surgical intervention. Postoperative follow-up period was 17.0±0.6 years. Primary endpoint was all-cause mortality, secondary endpoint — freedom from adverse cardiovascular events.

RESULTS

Cumulative survival rate was 48.6% and 69.5%, respectively (p=0.011). Assessment of the influence of additional factors on survival revealed significant result only for the predictor «age prior to surgery» (HR 1.04/year, p=0.0031). No significant result was obtained for the predictors «baseline ejection fraction» and «number of distal anastomoses» (p=0.1342 and p=0.5893, respectively). Regarding the likelihood of adverse cardiovascular events, both groups did not differ significantly (50.0% and 42.7%, respectively, p=0.34).

CONCLUSION

Perioperative therapy with 5-hydroxymethyluracil improved patient survival from 48.6% to 69.5% throughout 17.0±0.6 postoperative years without effect on the incidence of adverse cardiovascular events.